PacificHealth Laboratories, Inc. company was founded in 1995 and is based in Matawan, New Jersey. PacificHealth Laboratories, Inc. engages in the development, marketing, and sale of protein-based nutritional products for appetite regulation. It principally focuses on sports performance, weight loss, and management of Type II diabetes. The company offers ENDUROX R4, a recovery drink; ACCELERADE, a sports drink; ACCEL GEL, an energy gel; and ENDUROX EXCEL, a dietary supplement. PacificHealth Laboratories sells its products through retail outlets, including GNC, sports specialty stores, independent health food retailers, independent bike retailers, health clubs, catalogs, and Internet sites, as well as through independent distributors.

Ferndale Laboratories makes prescription and over the counter medications, with a primary focus on skin care maladies, including acne, dry skin, eczema, psoriasis, and inflammation. The company also makes topical pain relief creams, surgical adhesives and adhesive removers, and decongestants. Ferndale Laboratories markets its products to physicians and consumers. Ferndale company originally began selling vitamins, tonics, elixirs, and surgical instruments. It was founded in Detroit in 1897 as J. F. Hartz Company, the name it operated under until the mid-1950s when it changed its name to Ferndale Laboratories.

Aeolus Pharmaceuticals, Inc. was founded in 1994 and is based in Mission Viejo, California. Aeolus Pharmaceuticals, Inc. (Aeolus) is a pharmaceutical company engaged in development of medical countermeasures against biological, chemical and radiological weapons, as well as for diseases and disorders of the central nervous system, respiratory system, autoimmune system and oncology. The Company is testing its lead compound, AEOL 10150, in a range of indications each in various stages of development. The Company’s lead indications are a medical countermeasure against the effects of acute radiation syndrome (ARS) in the lungs and in the gastro-intestinal tract, and a medical countermeasure against the effects of sulfur mustard gas and chlorine gas. The Company is also developing its second drug candidate AEOL 11207 for the treatment of epilepsy and Parkinson’s disease.

United Research Laboratories (URL), along with sister company Mutual Pharmaceutical (together known as URL/Mutual), manufactures generic medications and conducts research on existing drug formulas through agreements with other pharmaceutical companies. URL/Mutual has developed generic versions of drugs manufactured by King, Ortho-McNeil, Merck, and Berlex, among others. The company has also developed its own proprietary drug delivery systems. URL and Mutual Pharmaceuticals are subsidiaries of URL Pharma (formerly Pharmaceutical Holdings Corporation).

Cytokinetics, Incorporated company was founded in 1997 and is headquartered in South San Francisco, California. Cytokinetics, Incorporated, a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule drug therapeutics for the treatment of cardiovascular diseases and cancer. The company’s lead product includes CK-1827452, a cardiac muscle myosin activator, which is in Phase IIa clinical trials for the treatment of heart failure. Its products under development stage comprise Ispinesib, a kinesin spindle protein inhibitor that is in Phase I/II clinical trials for the treatment of metastatic breast cancer; SB-743921, which is in Phase I/II trials to treat patients with non-Hodgkin or Hodgkin lymphoma; and GSK-923295, centromere-associated protein E inhibitor, which is in Phase I clinical trials to treat patients with refractory solid tumors. The company’s products under preclinical stage consist of CK-2017357, a skeletal sarcomere activator for the treatment of diseases and conditions associated with muscle weakness or wasting; and smooth muscle myosin inhibitor for the treatment of pulmonary arterial hypertension, and diseases and medical conditions associated with bronchoconstriction. It has a strategic alliance with Amgen Inc. to discover, develop, and commercialize novel small-molecule therapeutics that activate cardiac muscle contractility for applications in the treatment of heart failure, as well as with GlaxoSmithKline to develop GSK-923295.

Tridelta specialises in the development, manufacturing and marketing of diagnostic products for the animal health care industry. The company has commercialised five technologies to date with its "PHASE" range of Acute Phase Protein Assays, which are indicators of the presence of an inflammatory reaction, detected in the blood before the animal shows any physical signs of ill health. Species of specific interest include: cattle, horses, sheep, cats, dogs, pigs and rodents.

Novavax, Inc. was founded in 1987 and is headquartered in Rockville, Maryland. Novavax, Inc., a clinical-stage biopharmaceutical company, focuses on developing vaccines using its virus-like particle platform technology for infectious diseases. It develops vaccines against the H5N1 and other subtypes of avian influenza with pandemic potential, human seasonal influenza, and Respiratory Syncytial Virus, as well as Varicella Zoster that causes shingles. The company has a joint venture with Cadila Pharmaceuticals Ltd. to develop and commercialize seasonal influenza virus-like-particle-based vaccine candidates and therapeutic vaccine candidates against cancer, as well as adjuvants, biogeneric products, and other diagnostic products for the territory of India. It also has a strategic collaboration Xcellerex Inc. for the production of 2009 H1N1 influenza vaccine.

ALK is a global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. We are devoted to improving quality of life for people with allergies by developing pharmaceutical products that target the actual cause of allergy. ALK is the world leader in allergy vaccination (immunotherapy) – a unique treatment that induces a protective immune response which reduces and potentially halts the allergic reaction.

Founded in the early 1900s, LEO Pharma has about two dozen products on the market, many of which treat psoriasis, eczema, and skin infections. The company's other focus areas include developing and manufacturing treatments for blood clot disorders, kidney disease, and support drugs for cancer treatments. Products such as Daivobet, Innohep, and Xamiol are among its best sellers. LEO Pharma has operations in Europe, as well as in the US, Middle East, Africa, and Asia. The company is wholly-owned by the Leo Foundation, which is managed by members of LEO Pharma's executive team.

The Government Pharmaceutical Organization (GPO) provides the medicine that keeps Thai residents healthy. The organization researches and manufactures a wide variety of pharmaceutical products for ailments involving the respiratory, cardiovascular, and gastrointestinal systems, and vaccines, among others. GPO also makes vitamins, supplements, and diagnostic test kits. The organization's more than hundreds of pharmacists offer services through its about a dozen facilities, including retail drug stores. The Government Pharmaceutical Laboratories and the Division of Medical Depot merged to form GPO in 1966. The organization is part of Thailand's Ministry of Public Health.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.